OS Therapies reports Q2 2024 net operating loss of $1.557M; IPO raises $6.4M post-quarter

OS Therapies Inc

2024-Q2 EPS reported -$0.52

Q2 2024 net operating loss $1.557M vs $2.505M in Q2 2023; EPS loss $0.26 on 5.991M shares.
IPO on July 31, 2024 raised $6.4M gross with no warrants; all preferred shares and debt converted to equity.
Post-IPO shares outstanding: 20.85M common shares, with 1.86M tradable; 18.99M under 6-month lockup.
Lead program OST-HER2 Phase 2b osteosarcoma trial final results expected Q4 2024; interim data from 39/41 patients.
Cash runway extended to mid-2025 based on IPO proceeds; company reports no debt post-IPO.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.